{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:27:00Z","timestamp":1786602420078,"version":"build-2736575974"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021726","name":"Direktorat Riset and Pengembangan, Universitas Indonesia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021726","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Breast cancer is a heterogeneous disease in which accurate classification based on biomarker expression is essential for effective therapeutic decision-making. Consequently, the identification of novel biomarkers remains a research priority. Proprotein convertase subtilisin\/kexin type 9 (PCSK9), a key regulator of low-density lipoprotein (LDL) metabolism\n                      <jats:italic>via<\/jats:italic>\n                      its interaction with the LDL receptor (LDLR), has been extensively studied in cardiovascular disease. More recently, emerging evidence indicates that PCSK9 is highly expressed in several malignancies and may contribute to cancer progression, including in breast cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic literature review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) guidelines. PubMed (NCBI), Scopus, and Google Scholar were searched for studies published between 9 and 16 September 2025. Eligible studies included experimental (\n                      <jats:italic>in vitro, in vivo<\/jats:italic>\n                      , and\n                      <jats:italic>in silico<\/jats:italic>\n                      ) and clinical investigations evaluating the role of PCSK9 in breast cancer. Given the heterogeneity in study designs and outcomes, findings were synthesized narratively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen studies met the inclusion criteria. Preclinical evidence consistently demonstrates that PCSK9 promotes tumorigenesis by enhancing cell proliferation, migration, invasion, and metastasis, supporting its potential as a biomarker and therapeutic target. However, clinical findings remain inconsistent, with conflicting evidence regarding the association between PCSK9 expression and patient prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, while preclinical studies indicate a pro-tumorigenic role for PCSK9, its clinical significance in breast cancer appears to be context-dependent. The effects of PCSK9 vary according to molecular subtype and are influenced by the tumor microenvironment. Further well-designed studies are needed to clarify its prognostic value and potential as a target for personalized therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1849027","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:32:00Z","timestamp":1786599120000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of PCSK9 in breast cancer: a systematic review of its mechanistic pathways and clinical relevance"],"prefix":"10.3389","volume":"17","author":[{"given":"Meidi Utami","family":"Puteri","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia","place":["Depok, West Java, Indonesia"]},{"name":"National Metabolomics Collaborative Research Centre, Faculty of Pharmacy, Universitas Indonesia","place":["Depok, West Java, Indonesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicko","family":"Suswidiantoro","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universitas Indonesia","place":["Depok, Indonesia"]},{"name":"Laboratory of Pharmacology and Toxicology, Pharmacy Department, Faculty of Health, Universitas Aisyah Pringsewu","place":["Lampung, Indonesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Nabila","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universitas Indonesia","place":["Depok, Indonesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Setiawan","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universitas Indonesia","place":["Depok, Indonesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuriza Ulul","family":"Azmi","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia","place":["Depok, West Java, Indonesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadlina Chany","family":"Saputri","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia","place":["Depok, West Java, Indonesia"]},{"name":"National Metabolomics Collaborative Research Centre, Faculty of Pharmacy, Universitas Indonesia","place":["Depok, West Java, Indonesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihide","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Experimental Pathology, Institute of Medicine, University of Tsukuba","place":["Ibaraki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyasu","family":"Kato","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universitas Indonesia","place":["Depok, Indonesia"]},{"name":"Department of Experimental Pathology, Institute of Medicine, University of Tsukuba","place":["Ibaraki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"104847","DOI":"10.1016\/j.phrs.2020.104847","article-title":"Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor","volume":"158","author":"Abdelwahed","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/nu12051440","article-title":"Naturally occurring PCSK9 inhibitors","volume":"12","author":"Adorni","year":"2020","journal-title":"Nutrients"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.2174\/0109298673291217241219055416","article-title":"The expression of the LDLR, LDLRAP1, and PCSK9 genes has prognostic significance in triple-negative breast cancer","volume":"32","author":"Antipenko","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"B6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/biom16010067","article-title":"PCSK9 in cancer: biological mechanisms and implications for therapeutic resistance","volume":"16","author":"Azmi","year":"2025","journal-title":"Biomolecules"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00910-z","article-title":"The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells","volume":"8","author":"Baek","year":"2017","journal-title":"Nat. Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01690-3","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside","volume":"9","author":"Bao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0249628","DOI":"10.1371\/journal.pone.0249628","article-title":"Safety and efficacy of allylamines in the treatment of cutaneous and mucocutaneous leishmaniasis: a systematic review","volume":"16","author":"Bezemer","year":"2021","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"188581","DOI":"10.1016\/j.bbcan.2021.188581","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): a potential multifaceted player in cancer","volume":"1876","author":"Bhattacharya","year":"2021","journal-title":"Biochimica Biophysica Acta - Rev. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm8060853","article-title":"HDL and LDL: potential new players in breast cancer development","volume":"8","author":"Ced\u00f3","year":"2019","journal-title":"J. Clin. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/10742484221100107","article-title":"A comprehensive review of PCSK9 inhibitors","volume":"27","author":"Coppinger","year":"2022","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/OTT.S504637","article-title":"PCSK9 manipulates lipid metabolism and the immune microenvironment in cancer","volume":"18","author":"Cui","year":"2025","journal-title":"OncoTargets Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1016\/j.celrep.2019.05.104","article-title":"Increased cholesterol biosynthesis is a key characteristic of breast cancer stem cells influencing patient outcome","volume":"27","author":"Ehmsen","year":"2019","journal-title":"Cell Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"111871","DOI":"10.1016\/j.biopha.2021.111871","article-title":"Selective estrogen receptor modulators (SERMs) affect cholesterol homeostasis through the master regulators SREBP and LXR","volume":"141","author":"Fern\u00e1ndez-Su\u00e1rez","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"101510","DOI":"10.1016\/j.tranon.2022.101510","article-title":"Key signal transduction pathways and crosstalk in cancer: biological and therapeutic opportunities","volume":"26","author":"Fu","year":"2022","journal-title":"Transl. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e40066","DOI":"10.7759\/cureus.40066","article-title":"Luminal B, human epidermal growth factor receptor 2 (HER2\/neu), and triple-negative breast cancers associated with a better chemotherapy response than luminal A breast cancers in postneoadjuvant settings","volume":"15","author":"Hashmi","year":"2023","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers17040650","article-title":"Lipid metabolism in breast cancer: from basic research to clinical application","volume":"17","author":"Huang","year":"2025","journal-title":"Cancers"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/5932315","article-title":"Brazilin from Caesalpinia sappan L. as a proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitor: pharmacophore-based virtual screening, in silico molecular docking, and in vitro studies","volume":"2023","author":"Iqbal","year":"2023","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIRCGENETICS.116.001632","article-title":"PCSK9 loss-of-function variants, low-density lipoprotein cholesterol, and risk of coronary heart disease and stroke: data from 9 studies of blacks and whites","volume":"10","author":"Kent","year":"2017","journal-title":"Circ. Cardiovasc. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2408514","DOI":"10.1002\/advs.202408514","article-title":"PCSK9 promotes the malignancy of triple-negative breast cancer cells by reducing cholesterol levels at the plasma membrane to activate EGFR and HER3","volume":"12","author":"Li","year":"2025","journal-title":"Adv. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s12672-024-01684-9","article-title":"Comprehensive Mendelian randomization analysis of low-density lipoprotein cholesterol and multiple cancers","volume":"15","author":"Liang","year":"2024","journal-title":"Discov. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.62347\/brnk8140","article-title":"Polydatin ameliorates low-density lipoprotein cholesterol and lipid metabolism by downregulating proprotein convertase subtilisin\/kexin type 9 (PCSK9) in triple-negative breast cancer with hyperlipidemia","volume":"14","author":"Liu","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1218968","DOI":"10.3389\/fendo.2023.1218968","article-title":"A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022","volume":"14","author":"Luo","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"101043","DOI":"10.1016\/j.tranon.2021.101043","article-title":"Influence of cholesterol on cancer progression and therapy","volume":"14","author":"Mayengbam","year":"2021","journal-title":"Transl. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2024.11.009","article-title":"A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor","volume":"188","author":"Mei","year":"2025","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"570","DOI":"10.5114\/aoms.2019.84734","article-title":"Effects of immunization against PCSK9 in an experimental model of breast cancer","volume":"15","author":"Momtazi-Borojeni","year":"","journal-title":"Archives Med. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"","journal-title":"Eur. Heart J. - Cardiovasc. Pharmacother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: from biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm11154503","article-title":"Effect of serum lipid profile on the risk of breast cancer: systematic review and meta-analysis of 1,628,871 women","volume":"11","author":"Nouri","year":"2022","journal-title":"J. Clin. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-06467-9","article-title":"A Mendelian randomization study of the effects of blood lipids on breast cancer risk","volume":"9","author":"Nowak","year":"2018","journal-title":"Nat. Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/ijms23010533","article-title":"Cholesterol in the cell membrane\u2014an emerging player in atherogenesis","volume":"23","author":"Paukner","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1471-4159.2006.03928.x","article-title":"Implication of the proprotein convertase NARC-1\/PCSK9 in the development of the nervous system","volume":"98","author":"Poirier","year":"2006","journal-title":"J. Neurochem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (proprotein convertase subtilisin\/Kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36","volume":"143","author":"Qi","year":"2021","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers16071411","article-title":"Prognostic value of PCSK9 levels in premenopausal women at risk of breast cancer\u2014evidence from a 17-year follow-up study","volume":"16","author":"Ruscica","year":"2024","journal-title":"Cancers"},{"key":"B39","doi-asserted-by":"publisher","first-page":"141197","DOI":"10.1016\/j.molstruc.2024.141197","article-title":"From biosynthesis to therapeutics: a comprehensive review on varied functions of estrogen and selective estrogen receptor modulators","volume":"1327","author":"Sant","year":"2025","journal-title":"J. Mol. Struct."},{"key":"B40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12967-025-06126-w","article-title":"Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma","volume":"23","author":"Scalambra","year":"2025","journal-title":"J. Transl. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase rou: liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/life15121851","article-title":"The roles of PCSK9 in Alzheimer\u2019s disease: a systematic review of clinical, genetic, and preclinical evidence","volume":"15","author":"Suswidiantoro","year":"2025","journal-title":"Life"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms252413637","article-title":"The emerging role of PCSK9 in the pathogenesis of alzheimer\u2019s disease: a possible target for the disease treatment","volume":"25","author":"Testa","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s11357-025-01719-1","article-title":"Quantifying the impact of treatment delays on breast cancer survival outcomes: a comprehensive meta-analysis","volume":"48","author":"Ungvari","year":"","journal-title":"GeroScience"},{"key":"B45","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11357-025-01733-3","article-title":"PCSK9 expression and cancer survival: a prognostic biomarker at the intersection of oncology and geroscience","volume":"48","author":"Ungvari","year":"","journal-title":"GeroScience"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-025-02258-1","article-title":"Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment","volume":"24","author":"Wan","year":"2025","journal-title":"Mol. Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/genes15010132","article-title":"The causal relationship between PCSK9 inhibitors and drug targeting","volume":"15","author":"Wang","year":"2024","journal-title":"Genes"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00712-8","article-title":"PCSK9 in T-cell function and the immune response","volume":"12","author":"Wang","year":"2024","journal-title":"Biomark. Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/00368504211028395","article-title":"The significances and clinical implications of cholesterol components in human breast cancer","volume":"104","author":"Wei","year":"2021","journal-title":"Sci. Prog."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/ph18081095","article-title":"PCSK9 inhibitor and potential decreased risk of neoplasms, especially in females: a meta-analysis","volume":"18","author":"Wei","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1055\/s-0041-1735440","article-title":"The cancer genome Atlas pan-cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat. Genet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/path.1700130103","article-title":"On the occurrence of crystals in tumours","volume":"13","author":"White","year":"1909","journal-title":"J. Pathology Bacteriol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-022-10120-6","article-title":"Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers","volume":"22","author":"Wong Chong","year":"2022","journal-title":"BMC Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1515\/oncologie-2024-0542","article-title":"Prognostic implications of PCSK9 expression in HER2-positive breast cancer","volume":"27","author":"Wu","year":"2025","journal-title":"Oncologie"},{"key":"B55","doi-asserted-by":"publisher","first-page":"216512","DOI":"10.1016\/j.canlet.2023.216512","article-title":"The lipid metabolism remodeling: a hurdle in breast cancer therapy","volume":"582","author":"Xiao","year":"2024","journal-title":"Cancer Lett."},{"key":"B56","doi-asserted-by":"publisher","first-page":"15330338241241484","DOI":"10.1177\/15330338241241484","article-title":"Identification of breast cancer subtypes based on endoplasmic reticulum stress-related genes and analysis of prognosis and immune microenvironment in breast cancer patients","volume":"23","author":"Yi","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyag052","article-title":"Structured tools for assessing quality and risk of bias in Mendelian randomization studies: an updated systematic review","volume":"55","author":"Yu","year":"2026","journal-title":"Int. J. Epidemiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti\u2010cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"key":"B58","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.5317666","volume-title":"PCSK9-Mediated Metabolic Interactions Between Adipocytes and Triple-Negative Breast Cancer Cells Enhance Tumor Progression and Immune Evasion","author":"Zhai","year":"2025"},{"key":"B59","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s10552-024-01857-5","article-title":"Circulating lipids, lipid\u2010lowering drug targets, and breast cancer","volume":"35","author":"Zhang","year":"2024","journal-title":"Cancer Causes Control"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40001-025-02937-1","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach","volume":"30","author":"Zheng","year":"2025","journal-title":"Eur. J. Med. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1849027\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:32:02Z","timestamp":1786599122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1849027\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":59,"alternative-id":["10.3389\/fphar.2026.1849027"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1849027","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1849027"}}